Immunome Statistics
Share Statistics
Immunome has 62.42M shares outstanding. The number of shares has increased by 46.07% in one year.
| Shares Outstanding | 62.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.93% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 51.30M |
| Failed to Deliver (FTD) Shares | 125 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 8.80M, so 14.1% of the outstanding shares have been sold short.
| Short Interest | 8.80M |
| Short % of Shares Out | 14.1% |
| Short % of Float | 17.19% |
| Short Ratio (days to cover) | 8.68 |
Valuation Ratios
The PE ratio is -1.99 and the forward PE ratio is -4.31.
| PE Ratio | -1.99 |
| Forward PE | -4.31 |
| PS Ratio | 15.15 |
| Forward PS | 32.7 |
| PB Ratio | 1.77 |
| P/FCF Ratio | -25.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Immunome Inc. has an Enterprise Value (EV) of 6.77M.
| EV / Earnings | -0.06 |
| EV / Sales | 0.48 |
| EV / EBITDA | -0.24 |
| EV / EBIT | -0.06 |
| EV / FCF | -0.81 |
Financial Position
The company has a current ratio of 6.63, with a Debt / Equity ratio of 0.
| Current Ratio | 6.63 |
| Quick Ratio | 6.63 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.89% and return on capital (ROIC) is -90.12%.
| Return on Equity (ROE) | -0.89% |
| Return on Assets (ROA) | -0.72% |
| Return on Capital (ROIC) | -90.12% |
| Revenue Per Employee | 254.87K |
| Profits Per Employee | -1.94M |
| Employee Count | 55 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -32.66% in the last 52 weeks. The beta is 1.82, so Immunome 's price volatility has been higher than the market average.
| Beta | 1.82 |
| 52-Week Price Change | -32.66% |
| 50-Day Moving Average | 11.7 |
| 200-Day Moving Average | 13.89 |
| Relative Strength Index (RSI) | 31.77 |
| Average Volume (20 Days) | 801.04K |
Income Statement
In the last 12 months, Immunome had revenue of 14.02M and earned -106.81M in profits. Earnings per share was -5.38.
| Revenue | 14.02M |
| Gross Profit | -8.91M |
| Operating Income | -109.53M |
| Net Income | -106.81M |
| EBITDA | -28.27M |
| EBIT | -109.53M |
| Earnings Per Share (EPS) | -5.38 |
Balance Sheet
The company has 98.68M in cash and 1.65M in debt, giving a net cash position of 97.03M.
| Cash & Cash Equivalents | 98.68M |
| Total Debt | 1.65M |
| Net Cash | 97.03M |
| Retained Earnings | -222.81M |
| Total Assets | 256.90M |
| Working Capital | 204.51M |
Cash Flow
In the last 12 months, operating cash flow was -7.57M and capital expenditures -831.00K, giving a free cash flow of -8.40M.
| Operating Cash Flow | -7.57M |
| Capital Expenditures | -831.00K |
| Free Cash Flow | -8.40M |
| FCF Per Share | -0.42 |
Margins
Gross margin is -63.54%, with operating and profit margins of -781.35% and -761.92%.
| Gross Margin | -63.54% |
| Operating Margin | -781.35% |
| Pretax Margin | -761.92% |
| Profit Margin | -761.92% |
| EBITDA Margin | -201.68% |
| EBIT Margin | -781.35% |
| FCF Margin | -59.92% |
Dividends & Yields
IMNM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -57.36% |
| FCF Yield | -1.43% |
Analyst Forecast
The average price target for IMNM is $30, which is 219.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 219.8% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 7.26 |
| Piotroski F-Score | 3 |